BMRN vs. BIIB, INCY, UTHR, NBIX, EXEL, EXAS, RGEN, MDGL, HALO, and IONS
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry.
BioMarin Pharmaceutical vs. Its Competitors
Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.
Biogen has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.
87.9% of Biogen shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biogen had 1 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 10 mentions for Biogen and 9 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.87 beat Biogen's score of 0.75 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.
Biogen presently has a consensus price target of $188.48, indicating a potential upside of 44.84%. BioMarin Pharmaceutical has a consensus price target of $93.61, indicating a potential upside of 63.05%. Given BioMarin Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.
BioMarin Pharmaceutical has a net margin of 17.76% compared to Biogen's net margin of 15.07%. Biogen's return on equity of 14.03% beat BioMarin Pharmaceutical's return on equity.
Summary
BioMarin Pharmaceutical beats Biogen on 11 of the 16 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:BMRN) was last updated on 7/7/2025 by MarketBeat.com Staff
